Restricted accessResearch articleFirst published online 2016-10
Comprehensive Laboratory Evaluation of a Highly Specific Lateral Flow Assay for the Presumptive Identification of Bacillus anthracis Spores in Suspicious White Powders and Environmental Samples
We conducted a comprehensive, multiphase laboratory evaluation of the Anthrax BioThreat Alert® test strip, a lateral flow immunoassay (LFA) for the rapid detection of Bacillus anthracis spores. The study, conducted at 2 sites, evaluated this assay for the detection of spores from the Ames and Sterne strains of B. anthracis, as well as those from an additional 22 strains. Phylogenetic near neighbors, environmental background organisms, white powders, and environmental samples were also tested. The Anthrax LFA demonstrated a limit of detection of about 106 spores/mL (ca. 1.5 × 105 spores/assay). In this study, overall sensitivity of the LFA was 99.3%, and the specificity was 98.6%. The results indicated that the specificity, sensitivity, limit of detection, dynamic range, and repeatability of the assay support its use in the field for the purpose of qualitatively evaluating suspicious white powders and environmental samples for the presumptive presence of B. anthracis spores.
The authors conducted a comprehensive, multiphase laboratory evaluation of the Anthrax BioThreat Alert® test strip, a lateral flow immunoassay (LFA) for the rapid detection of Bacillus anthracis spores. The study, conducted at 2 sites, evaluated this assay for the detection of spores from the Ames and Sterne strains of B. anthracis, as well as those from an additional 22 strains. The results indicated that the specificity, sensitivity, limit of detection, dynamic range, and repeatability of the assay support its use in the field for the purpose of qualitatively evaluating suspicious white powders and environmental samples for the presumptive presence of B. anthracis spores.
Get full access to this article
View all access options for this article.
References
1.
BouzianasDG. Medical countermeasures to protect humans from anthrax bioterrorism. Trends Microbiol, 2009; 17(11):522-528.
2.
BrossierF, MockM. Toxins of Bacillus anthracis. Toxicon, 2001; 39(11):1747-1755.
3.
JamieWE. Anthrax: diagnosis, treatment, prevention. Primary Care Update for OB/GYNS, 2002; 9:117-121.
HelgasonE, ØkstadOA, CaugantDA, et al.Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis—one species on the basis of genetic evidence. Appl Environ Microbiol, 2000; 66(6):2627-2630.
6.
PiloP, FreyJ. Bacillus anthracis: molecular taxonomy, population genetics, phylogeny and patho-evolution. Infect Genet Evol, 2011; 11(6):1218-1224.
7.
DragonDC, RennieRP. The ecology of anthrax spores: tough but not invincible. Can Vet J, 1995; 36(5):295-301.
8.
RussellAD, HugoWB, AyliffeGAJ. Principles and Practice of Disinfection, Preservation and Sterilization. 3d ed. Malden, MA: Blackwell Science; 1999.
9.
DriksA. The Bacillus anthracis spore. Mol Aspects Med, 2009; 30:368-373.
LiuX, WangD, RenJ, et al.Identification of the immunogenic spore and vegetative proteins of Bacillus anthracis vaccine strain A16R. PLoS One, 2013; 8(3):e57959.
12.
CoteCK, WelkosSL, BozueJ. Key aspects of the molecular and cellular basis of inhalational anthrax. Microbes Infect, 2011; 13(14-15):1146-1155.
13.
FouetA. The surface of Bacillus anthracis. Mol Aspects Med, 2009; 30:374-385.
14.
Balali-MoodM, MoshiriM, EtemadL. Medical aspects of bio-terrorism. Toxicon, 2013; 69:131-142.
15.
GuttingBW, GaskeKS, SchillingAS, et al.Differential susceptibility of macrophage cell lines to Bacillus anthracis-Vollum 1B. Toxicol in Vitro, 2005; 19(2):221-229.
16.
EzzellJWJr, WelkosSL. The capsule of Bacillus anthracis, a review. J Appl Microbiol, 1999; 87:250.
17.
UchidaL, HashimotoK, TerakadoN. Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harbouring or lacking 110 Mda and 60Mda plasmids. J Gen Microbiol, 1986; 132:557-559.
18.
KohoutE, SehatA, AshrafM. Anthrax: a continuous problem in southwest Iran. Am J Med Sci, 1964; 247:565-575.
19.
MockM, FouetA. Anthrax. Annu Rev Microbiol, 2001; 55:647-671.
20.
CavalloJD, RamisseF, GirardetM, VaissaireJ, MockM, HernandezE. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother, 2002; 46(7):2307-2309.
21.
Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep, 2001; 50(43):941-948.
22.
BellDM, KozarskyPE, StephensDS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis, 2002; 8:222-225.
23.
Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax, 2001. MMWR Morb Mortal Wkly Rep, 2001; 50(45):1008-1010.
24.
FriedlanderAM, WelkosSL, PittMLM, et al.Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis, 1993; 167(5):1239-1243.
HoltyJC, BravataDM, LiuH, OlshenRA, McDonaldKM, OwensDK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med, 2006; 144:270-280.
27.
CieslakTJ, EitzenEMJr.1999. Clinical and epidemiologic principles of anthrax. Emerg Infect Dis, 1999; 5:552-555.
28.
PickeringAK, OsorioM, LeeGM, GrippeVK, BrayM, MerkelTJ. Cytokine response to infection with Bacillus anthracis spores. Infect Immun, 2004; 72:6382-6389.
29.
FennellyKP, DavidowAL, MillerSL, ConnellN, EllnerJJ. Airborne infection with Bacillus anthracis—from mills to mail. Emerg Infect Dis, 2004; 10:996-1001.
30.
KarginovVA, RobinsonTM, RiemenschneiderJ, et al.Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol Med Microbiol, 2004; 40:71-74.
31.
PetersCJ, HartleyDM. 2002. Anthrax inhalation and lethal human infection. Lancet, 2002; 359:710-711.
32.
MorseSA, KelloggRB, PerryS, et al.Detecting biothreat agents: the Laboratory Response Network. ASM News, 2003; 69:433-437.
33.
HodgeDR, PrenticeKW, RamageJG, et al.Comprehensive laboratory evaluation of a highly specific lateral flow assay for the presumptive identification of ricin in suspicious white powders and environmental samples. Biosecur Bioterror, 2013; 11:237-250.
34.
RamageJG, PrenticeKW, MorseSA, et al.Comprehensive laboratory evaluation of a specific lateral flow assay for the presumptive identification of abrin in suspicious white powders and environmental samples. Biosecur Bioterror, 2014; 12:49-62.
35.
AOAC SMPR 2010.004. Standard method performance requirements for immunological-based handheld assays (HHAs) for the detection of Bacillus anthracis spores in visible powders. J AOAC Int, 2011; 94(4):1352-1355.
CLSI. Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline—Second Edition. CLSI document EP17-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
38.
FranzDR. Preparedness for an anthrax attack. Mol Aspects Med, 2009; 30:503-510.
39.
HoffmasterAR, MeyerRF, BowenMP, et al.Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis. Emerg Infect Dis, 2002; 8:1178-1182.
40.
AlamSI, AgarwalGS, KambojDV, RaiGP, SinghL. Detection of spores of Bacillus anthracis from environment using polymerase chain reaction. Indian J Exp Biol, 2003; 41:177-180.
41.
ChristensenDR, HartmanLJ, LovelessBM, et al.Detection of biological threat agents by real-time PCR: comparison of assay performance on the R.A.P.I.D., the LightCycler, and the Smart Cycler platforms. Clin Chem, 2006; 52:141-145.
42.
MorelN, VollandH, DanoJ, et al.Fast and sensitive detection of Bacillus anthracis spores by immunoassay. Appl Environ Microbiol, 2012; 78:6491-6498.
43.
RaoSS, MohanKVK, AtreyaCD. Detection technologies for Bacillus anthracis: prospects and challenges. J Microbiol Meth, 2010; 82:1-10.
44.
TimsTB, LimDV. Rapid detection of Bacillus anthracis spores directly from powders with an evanescent wave fiber-optic biosensor. J Microbiol Meth, 2004; 59:127-130.
45.
HangJ, SundaramAK, ZhuP, et al.Development of a rapid and sensitive immunoassay for detection and subsequent recovery of Bacillus anthracis spores in environmental samples. J Microbiol Meth, 2008; 73:242-246.
46.
CampbellGA, MutharasanR. Method of measuring Bacillus anthracis spores in the presence of copious amounts of Bacillus thuringiensis and Bacillus cereus. Anal Chem, 2007; 79:1145-1152.
47.
HadfieldT, RyanV. 2013. RAZOR™ EX anthrax air detection system for detection of Bacillus anthracis spores from aerosol collection samples: collaborative study. J AOAC Int, 2013; 96:392-398.
48.
GubalaV, HarrisLF, RiccoAJ, TanMX, WilliamsDE. Point of care diagnostics: status and future. Anal Chem, 2012; 84:487-515.
TownsendMB, MacNeilA, ReynoldsMG, et al.Evaluation of the Tetracore Orthopox BioThreat® antigen detection assay using laboratory grown orthopoxviruses and rash illness clinical specimens. J Virol Meth, 2013; 187:37-42.
51.
TomasoH, ThullierP, SeiboldE, et al.Comparison of hand-held test kits, immunofluorescence microscopy, enzyme-linked immunosorbent assay, and flow cytometric analysis for rapid presumptive identification of Yersinia pestis. J Clin Microbiol, 2007; 45(10):3404-3407.
52.
GesslerF, Pagel-WiederS, AvondetMA, BöhnelH. Evaluation of lateral flow assays for the detection of botulinum neurotoxin type A and their application in laboratory diagnosis of botulism. Diagn Microbiol Infect Dis, 2007; 57:243-249.
53.
IuraK, TsugeK, SetoY, SatoA. Detection of proteinous toxins using the BioThreat Alert system. Japanese Journal of Forensic Toxicology, 2004; 22:13-16.
54.
KingD, LunaV, CannonsA, CattaniJ, AmusoP. Performance assessment of three commercial assays for direct detection of Bacillus anthracis spores. J Clin Microbiol, 2003; 41:3454-3455.
